Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ddr.21701 http://scihub22266oqcxt.onion/10.1002/ddr.21701 32524646!7307055!32524646     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Dev+Res 2020 ; 81 (7): 782-785 Nephropedia Template TP {{tp|p=32524646|t=2020. Lithium as a candidate treatment for COVID-19: Promises and pitfalls |pdf=|usr=}}{{32524646}} gab.com Text Lithium as a candidate treatment for COVID-19: Promises and pitfalls JO: Drug Dev Res http://www.kidney.de/pget.php?&tw=1&pmid=32524646 #FOAvip The pandemic of respiratory illness caused by a novel coronavirus (SARS-nCoV-2) is a global health crisis. Despite numerous preliminary results, there is as yet no treatment of proven efficacy for this condition. In this context, the pharmacological properties of lithium, better known as a treatment for mood disorders, merit closer examination. Lithium has shown in vitro efficacy at inhibiting the replication of coronaviruses responsible for gastrointestinal and respiratory diseases in animals. It has immunomodulatory properties that may be of additional benefit in moderating the host inflammatory response to the novel coronavirus (SARS-CoV-2). Furthermore, there is evidence that lithium may exert a protective action against upper respiratory infections and influenza-like illnesses in patients taking it for other indications. These promising reports must be balanced against the narrow therapeutic index and high risk of toxicity associated with lithium therapy, its documented interactions with several commonly used drugs, and the absence of evidence of its efficacy against coronaviruses responsible for human disease. Nevertheless, naturalistic studies of the risk of COVID-19 in patients already receiving lithium could provide indirect evidence of its efficacy, and understanding the putative antiviral and immune-regulatory mechanisms of lithium in models of SARS-CoV-2 infection may provide leads for the development of safer and more effective treatments with a specific action against COVID-19. Twit Text FOAVip Lithium as a candidate treatment for COVID-19: Promises and pitfalls ????Drug Dev Res http://www.kidney.de/pget.php?&tw=1&pmid=32524646 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32524646 #FOAvip English Wikipedia <ref>{{Cite pmid|32524646}}</ref> Lithium as a candidate treatment for COVID-19: Promises and pitfalls #MMPMID32524646 Rajkumar RP Drug Dev Res 2020[Nov]; 81 (7): 782-785 PMID32524646show ga The pandemic of respiratory illness caused by a novel coronavirus (SARS-nCoV-2) is a global health crisis. Despite numerous preliminary results, there is as yet no treatment of proven efficacy for this condition. In this context, the pharmacological properties of lithium, better known as a treatment for mood disorders, merit closer examination. Lithium has shown in vitro efficacy at inhibiting the replication of coronaviruses responsible for gastrointestinal and respiratory diseases in animals. It has immunomodulatory properties that may be of additional benefit in moderating the host inflammatory response to the novel coronavirus (SARS-CoV-2). Furthermore, there is evidence that lithium may exert a protective action against upper respiratory infections and influenza-like illnesses in patients taking it for other indications. These promising reports must be balanced against the narrow therapeutic index and high risk of toxicity associated with lithium therapy, its documented interactions with several commonly used drugs, and the absence of evidence of its efficacy against coronaviruses responsible for human disease. Nevertheless, naturalistic studies of the risk of COVID-19 in patients already receiving lithium could provide indirect evidence of its efficacy, and understanding the putative antiviral and immune-regulatory mechanisms of lithium in models of SARS-CoV-2 infection may provide leads for the development of safer and more effective treatments with a specific action against COVID-19. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/pharmacology/*therapeutic use[MESH] |Lithium/pharmacology/*therapeutic use[MESH] |Pragmatic Clinical Trials as Topic[MESH] |SARS-CoV-2/drug effects[MESH]Lithium as a candidate treatment for COVID-19: Promises and pitfalls (epmc).pdf DeepDyve Pubget Overpricing